Natrunix
Phase 2Small molecule
Natrunix is one of 78 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
181 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Voltaren
NovartisPreclinical
Cataflam
NovartisPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Natrunix
XXBiotech, Inc.
Phase 2
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Natrunix. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- XXBiotech, Inc.